Can Dendreon’s new Provenge data help ignite a turnaround for the faded cancer star?
Two years ago, when Valeant bought Dendreon and its prostate cancer cell therapy Provenge out of bankruptcy for $400 million, observers marked it as another …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.